

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C07H 17/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/03461</b> <b>(43) International Publication Date:</b> <b>5 March 1992 (05.03.92)</b>
<b>(21) International Application Number:</b> PCT/US91/05939 <b>(22) International Filing Date:</b> 20 August 1991 (20.08.91)  <b>(30) Priority data:</b> 573,648 24 August 1990 (24.08.90) US  <b>(71) Applicant:</b> IXSYS, INC. [US/US]; 3550 General Atomics Court, Suite L103, San Diego, CA 92121 (US). <b>(72) Inventor:</b> HUSE, William, D. ; 471 Avenida Primavera, Del Mar, CA 92014 (US). <b>(74) Agents:</b> CAMPBELL, Cathryn et al.; Pretty, Schroeder, Brueggemann & Clark, 444 South Flower Street, Suite 2000, Los Angeles, CA 90071 (US).		<b>(81) Designated States:</b> AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU <sup>+</sup> , TD (OAPI patent), TG (OAPI patent).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHODS OF SYNTHESIZING OLIGONUCLEOTIDES WITH RANDOM CODONS  <b>(57) Abstract</b>  The invention provides a method of synthesizing oligonucleotides having random triplets using individual monomers. The steps consist of: (1) sequentially coupling monomers on separate supports to form at least two different triplets, the coupling is performed in separate reaction vessels; (2) mixing the supports from the reaction vessels; (3) dividing the mixed supports into two or more separate reaction vessels; and (4) repeating steps (1) through (3) one or more times in the reaction vessels of step (3), wherein the last step ends at step (2). Additionally, the oligonucleotides can be cleaved from the supports.		

\* See back of page

BEST AVAILABLE COPY

# + DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

METHODS OF SYNTHESIZING OLIGONUCLEOTIDES  
WITH RANDOM CODONS

BACKGROUND OF THE INVENTION

This invention relates generally to oligonucleotide  
5 synthesis and, more particularly, to methods of  
synthesizing oligonucleotides having random codons using  
individual monomers.

The speed and availability of automated nucleic acid  
synthesis has led to rapid technological advances in  
10 biological research. For example, the availability of  
synthetic primers for sequencing has permitted researchers  
to decrease their time and labor involved in sequencing a  
particular nucleic acid by approximately sixty percent.  
Another technology which is facilitated by synthetic  
15 oligonucleotides is the polymerase chain reaction (PCR).  
This technique, which involves the exponential  
amplification of sequences between two synthetic primers,  
offers unprecedented detection levels and permits genetic  
manipulation of the amplified sequence. Further, the  
20 availability of synthetic primers allows a variety of  
genetic manipulations to be performed with relatively  
simple procedures, including site-specific mutagenesis and  
the custom design of genetic vectors.

Sequences to be cloned are also routinely modified  
25 with synthetic oligonucleotides. The modifications of  
either vector or insert sequence can range from the  
addition of a simple sequence encoding a restriction enzyme  
site to more complicated schemes involving modifying the  
translation product of the cloned sequence with a specific  
30 peptide or a variety of peptide sequences. Thus, these  
technological advances associated with synthetic  
oligonucleotides has afforded researchers many  
opportunities to study diverse biological phenomenon in  
greater detail and with greater speed and accuracy.

Oligonucleotide synthesis proceeds via linear coupling of individual monomers in a stepwise reaction. The reactions are generally performed on a solid phase support by first coupling the 3' end of the first monomer to the support. The second monomer is added to the 5' end of the first monomer in a condensation reaction to yield a dinucleotide coupled to the solid support. At the end of each coupling reaction, the by-products and unreacted, free monomers are washed away so that the starting material for the next round of synthesis is the pure oligonucleotide attached to the support. In this reaction scheme, the stepwise addition of individual monomers to a single, growing end of a oligonucleotide ensures accurate synthesis of the desired sequence. Moreover, unwanted side reactions are eliminated, such as the condensation of two oligonucleotides, resulting in high product yields.

In some instances, it is desired that synthetic oligonucleotides have random nucleotide sequences. This result can be accomplished by adding equal proportions of all four nucleotides in the monomer coupling reactions, leading to the random incorporation of all nucleotides and yields a population of oligonucleotides with random sequences. Since all possible combinations of nucleotide sequences are represented within the population, all possible codon triplets will also be represented. If the objective is ultimately to generate random peptide products, this approach has a severe limitation because the random codons synthesized will bias the amino acids incorporated during translation of the DNA by the cell into polypeptides.

The bias is due to the redundancy of the genetic code. There are four nucleotide monomers which leads to sixty-four possible triplet codons. With only twenty amino acids to specify, many of the amino acids are encoded by multiple codons. Therefore, a population of oligonucleotides

synthesized by sequential addition of monomers from a random population will not encode peptides whose amino acid sequence represents all possible combinations of the twenty different amino acids in equal proportions. That is, the frequency of amino acids incorporated into polypeptides will be biased toward those amino acids which are specified by multiple codons.

To alleviate amino acid bias due to the redundancy of the genetic code, the oligonucleotides can be synthesized from nucleotide triplets. Here, a triplet coding for each of the twenty amino acids is synthesized from individual monomers. Once synthesized, the triplets are used in the coupling reactions instead of individual monomers. By mixing equal proportions of the triplets, synthesis of oligonucleotides with random codons can be accomplished. However, the cost of synthesis from such triplets far exceeds that of synthesis from individual monomers because triplets are not commercially available.

There thus exists a need for a method to synthesize oligonucleotides with random codons which alleviates genetic redundancy incurred through present synthesis methods using individual monomers and does not have the prohibitive costs associated with methods using pre-synthesized triplets. The present invention satisfies these needs and provides additional advantages as well.

#### SUMMARY OF THE INVENTION

The invention provides a method of synthesizing oligonucleotides having random tuplets using individual monomers. The steps consist of: sequentially coupling monomers on separate supports to form at least two different tuplets, the coupling is performed in separate reaction vessels; mixing the supports from the reaction vessels; dividing the mixed supports into two or more

separate reaction vessels; and repeating the coupling, mixing and dividing steps one or more times in the reaction vessels, ending with a mixing or dividing step. Additionally, the oligonucleotides can be cleaved from the supports.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic drawing for synthesizing oligonucleotides from nucleotide monomers with random tuplets at each position using twenty reaction vessels.

10 Figure 2 is a schematic drawing for synthesizing oligonucleotides from nucleotide monomers with random tuplets at each position using ten reaction vessels.

#### DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to a simple and inexpensive method for synthesizing oligonucleotides having random tuplets using individual monomers. The method is advantageous in that individual monomers are used instead of tuplets. The monomers are commercially available in a form which can be used in oligonucleotide synthesis and are inexpensive. An additional advantage of the method is that it can alleviate codon redundancy inherent in present methods of random synthesis by utilizing only a non-degenerate subset of all triplets. Thus, the method is able to produce a large proportion of possible oligonucleotides with random tuplets. The oligonucleotides produced are useful for making an unlimited number of pharmacological and research products.

In a preferred embodiment, the invention entails the sequential coupling of monomers to produce oligonucleotides with random codons. The coupling reactions for the randomization of twenty codons which specify the amino

acids of the genetic code are performed in ten different reaction vessels. Each reaction vessel contains a support on which the monomers for two different codons are coupled in three sequential reactions. One of the reactions couple  
5 an equal mixture of two monomers such that the final product has a sequence of two different codons. The codons are randomized by removing the supports from the reaction vessels and mixing them to produce a single batch of supports containing all twenty codons. Synthesis at the  
10 next codon position proceeds by equally dividing the mixed batch of supports into ten reaction vessels as before and sequentially coupling the monomers for each pair of codons. The supports are again mixed to randomize the codons at the position just synthesized. The cycle of coupling, mixing  
15 and dividing continues until the desired number of codon positions have been randomized. After the last position has been randomized, the oligonucleotides with random codons are cleaved from the support.

As used herein, the term "monomer" or "nucleotide  
20 monomer" refers to individual nucleotides used in the chemical synthesis of oligonucleotides. Monomers that can be used include both the ribo- and deoxyribo- forms of each of the five standard nucleotides (derived from the bases adenine (A or dA, respectively), guanine (G or dG),  
25 cytosine (C or dC), thymine (T) and uracil (U)). Derivatives and precursors of bases such as inosine which are capable of supporting polypeptide biosynthesis are also included as monomers. Also included are chemically modified nucleotides, for example, one having a reversible  
30 blocking agent attached to any of the positions on the purine or pyrimidine bases, the ribose or deoxyribose sugar or the phosphate or hydroxyl moieties of the monomer. Such blocking groups include, for example, dimethoxytrityl, benzoyl, isobutyryl, beta-cyanoethyl and diisopropylamine  
35 groups, and are used to protect hydroxyls, exocyclic amines and phosphate moieties. Other blocking agents can also be

used and are known to one skilled in the art.

As used herein, the term "tuplet" refers to a group of elements of a definable size. The elements of a tuplet as used herein are nucleotide monomers. For example, a tuplet  
5 can be a dinucleotide, a trinucleotide or can also be four or more nucleotides.

As used herein, the term "codon" or "triplet" refers to a tuplet consisting of three adjacent nucleotide monomers which specify one of the twenty naturally  
10 occurring amino acids found in polypeptide biosynthesis. The term also includes nonsense codons which do not specify any amino acid.

"Random codons" or "randomized codons," as used herein, refers to more than one codon at a position within  
15 a collection of oligonucleotides. The number of different codons can be from two to twenty at any particular position. "Randomized oligonucleotides," as used herein, refers to a collection of oligonucleotides with random codons at one or more positions. For example, if the  
20 randomized oligonucleotides are six nucleotides in length (i.e., two codons) and both the first and second codon positions are randomized to encode all twenty amino acids, then a population of oligonucleotides with every possible combination of the twenty triplets in the first and second  
25 position makes up the above population of randomized oligonucleotides. The number of possible codon combinations is  $20^2$ . Likewise, if randomized oligonucleotides of fifteen nucleotides in length are synthesized which are randomized at all positions, then all  
30 triplets coding for each of the twenty amino acids will be found in equal proportions at every position. The population constituting the randomized oligonucleotides will contain  $20^{15}$  different possible species of oligonucleotides. "Random tuplets," or "randomized



tuplets" are defined analogously.

As used herein, the term "support" refers to a solid phase material for attaching monomers for chemical synthesis. Such support is usually composed of materials  
5 such as beads of control pore glass but can be other materials known to one skilled in the art. The term is also meant to include one or more monomers coupled to the support for additional oligonucleotide synthesis reactions.

As used herein, the terms "coupling" or "condensing"  
10 refers to the chemical reactions for attaching one monomer to a second monomer or to a solid support. Such reactions are known to one skilled in the art and are typically performed on an automated DNA synthesizer such as a MilliGen/Biosearch Cyclone Plus Synthesizer using  
15 procedures recommended by the manufacturer. "Sequentially coupling" as used herein, refers to the stepwise addition of monomers.

The invention provides a method of synthesizing oligonucleotides having random tuplets using individual  
20 monomers. The method comprises several steps, the first being synthesis of a nucleotide tuple for each tuple to be randomized. As described here and below, a nucleotide triplet (i.e., a codon) will be used as a specific example of a tuple. Any size tuple will work using the methods  
25 disclosed herein, and one skilled in the art would know how to use the methods to randomize tuplets of any size.

If the randomization of codons specifying all twenty amino acids is desired at a position, then twenty different codons are synthesized. Likewise, if randomization of only  
30 ten codons at a particular position is desired then those ten codons are synthesized. Randomization of codons from two to sixty-four can be accomplished by synthesizing each desired triplet. Preferably, randomization of from two to

twenty codons is used for any one position because of the redundancy of the genetic code. The codons selected at one position do not have to be the same codons selected at the next position. Additionally, the sense or anti-sense  
5 sequence oligonucleotide can be synthesized. The process therefore provides for randomization of any desired codon position with any number of codons.

Codons to be randomized are synthesized sequentially by coupling the first monomer of each codon to separate  
10 supports. The supports for the synthesis of each codon can, for example, be contained in different reaction vessels such that one reaction vessel corresponds to the monomer coupling reactions for one codon. As will be used here and below, if twenty codons are to be randomized, then  
15 twenty reaction vessels can be used in independent coupling reactions for the first twenty monomers of each codon. Synthesis proceeds by sequentially coupling the second monomer of each codon to the first monomer to produce a dimer, followed by coupling the third monomer for each  
20 codon to each of the above-synthesized dimers to produce a trimer (Figure 1, step 1, where  $M_1$ ,  $M_2$  and  $M_3$  represent the first, second and third monomer, respectively, for each codon to be randomized).

Following synthesis of the first codons from  
25 individual monomers, the randomization is achieved by mixing the supports from all twenty reaction vessels which contain the individual codons to be randomized. The solid phase support can be removed from its vessel and mixed to achieve a random distribution of all codon species within  
30 the population (Figure 1, step 2). The mixed population of supports, constituting all codon species, are then redistributed into twenty independent reaction vessels (Figure 1, step 3). The resultant vessels are all identical and contain equal portions of all twenty codons  
35 coupled to a solid phase support.

For randomization of the second position codon, synthesis of twenty additional codons is performed in each of the twenty reaction vessels produced in step 3 as the condensing substrates of step 1 (Figure 1, step 4). Steps 1 and 4 are therefore equivalent except that step 4 uses the supports produced by the previous synthesis cycle (steps 1 through 3) for codon synthesis whereas step 1 is the initial synthesis of the first codon in the oligonucleotide. The supports resulting from step 4 will each have two codons attached to them (i.e., a hexanucleotide) with the codon at the first position being any one of twenty possible codons (i.e., random) and the codon at the second position being one of the twenty possible codons.

For randomization of the codon at the second position and synthesis of the third position codon, steps 2 through 4 are again repeated. This process yields in each vessel a three codon oligonucleotide (i.e., 9 nucleotides) with codon positions 1 and 2 randomized and position three containing one of the twenty possible codons. Steps 2 through 4 are repeated to randomize the third position codon and synthesize the codon at the next position. The process is continued until an oligonucleotide of the desired length is achieved. After the final randomization step, the oligonucleotide can be cleaved from the supports and isolated by methods known to one skilled in the art. Alternatively, the oligonucleotides can remain on the supports for use in methods employing probe hybridization.

The diversity of codon sequences, i.e., the number of different possible oligonucleotides, which can be obtained using the methods of the present invention, is extremely large and only limited by the physical characteristics of available materials. For example, a support composed of beads of about 100  $\mu\text{m}$  in diameter will be limited to about

10,000 beads/reaction vessel using a 1  $\mu$ M reaction vessel containing 25 mg of beads. This size bead can support about  $1 \times 10^7$  oligonucleotides per bead. Synthesis using separate reaction vessels for each of the twenty amino acids will produce beads in which all the oligonucleotides attached to an individual bead are identical. The diversity which can be obtained under these conditions is approximately  $10^7$  copies of 10,000  $\times$  20 or 200,000 different random oligonucleotides. The diversity can be increased, however, in several ways without departing from the basic methods disclosed herein. For example, the number of possible sequences can be increased by decreasing the size of the individual beads which make up the support. A bead of about 30  $\mu$ m in diameter will increase the number of beads per reaction vessel and therefore the number of oligonucleotides synthesized. Another way to increase the diversity of oligonucleotides with random codons is to increase the volume of the reaction vessel. For example, using the same size bead, a larger volume can contain a greater number of beads than a smaller vessel and therefore support the synthesis of a greater number of oligonucleotides. Increasing the number of codons coupled to a support in a single reaction vessel also increases the diversity of the random oligonucleotides. The total diversity will be the number of codons coupled per vessel raised to the number of codon positions synthesized. For example, using ten reaction vessels, each synthesizing two codons to randomize a total of twenty codons, the number of different oligonucleotides of ten codons in length per 100  $\mu$ m bead can be increased where each bead will contain about  $2^{10}$  or  $1 \times 10^3$  different sequences instead of one. One skilled in the art will know how to modify such parameters to increase the diversity of oligonucleotides with random codons.

35       The invention provides for a method of synthesizing oligonucleotides having random codons at each position

using individual monomers wherein the number of reaction vessels is less than the number of codons to be randomized. For example, if twenty codons are to be randomized at each position within an oligonucleotide population, then ten  
5 reaction vessels can be used. The use of a smaller number of reaction vessels than the number of codons to be randomized at each position is preferred because the smaller number of reaction vessels is easier to manipulate and results in a greater number of possible  
10 oligonucleotides synthesized.

The use of a smaller number of reaction vessels for random synthesis of twenty codons at a desired position within an oligonucleotide is similar to that described above using twenty reaction vessels except that each  
15 reaction vessel can contain the synthesis products of more than one codon. For example, step one synthesis using ten reaction vessels proceeds by coupling about two different codons on supports contained in each of ten reaction vessels. This is shown in Figure 2 where each of the two  
20 codons coupled to a different support can consist of the following sequences: (1) (T/G)TT for Phe and Val; (2) (T/C)CT for Ser and Pro; (3) (T/C)AT for Tyr and His; (4) (T/C)GT for Cys and Arg; (5) (C/A)TG for Leu and Met; (6) (C/G)AG for Gln and Glu; (7) (A/G)CT for Thr and Ala; (8)  
25 (A/G)AT for Asn and Asp; (9) (T/G)GG for Trp and Gly and (10) A(T/A)A for Ile and Cys. The slash (/) signifies that a mixture of the monomers indicated on each side of the slash are used as if they were a single monomer in the indicated coupling step. The antisense sequence for each  
30 of the above codons can be generated by synthesizing the complementary sequence. For example, the antisense for Phe and Val can be AA(C/A). The amino acids encoded by each of the above pairs of sequences are given as the standard three letter nomenclature.

Coupling of the monomers in this fashion will yield codons specifying all twenty of the naturally occurring amino acids attached to supports in ten reaction vessels. However, the number of individual reaction vessels to be  
5 used will depend on the number of codons to be randomized at the desired position and can be determined by one skilled in the art. For example, if ten codons are to be randomized, then five reaction vessels can be used for coupling. The codon sequences given above can be used for  
10 this synthesis as well. The sequences of the codons can also be changed to incorporate or be replaced by any of the additional forty-four codons which constitutes the genetic code.

The remaining steps of synthesis of oligonucleotides  
15 with random codons using a smaller number of reaction vessels are as outlined above for synthesis with twenty reaction vessels except that the mixing and dividing steps are performed with supports from about half the number of reaction vessels. These remaining steps are shown in  
20 Figure 2 (steps 2 through 4).

The invention also provides a method of synthesizing oligonucleotides using individual monomers having at least one specified tuplet at a predetermined position and the remaining positions having random tuplets. The synthesis  
25 steps are similar to those outlined above using twenty or less reaction vessels except that prior to synthesis of the specified codon position, the dividing of the supports into separate reaction vessels for synthesis of different codons is omitted. For example, if the codon at the second  
30 position of the oligonucleotide is to be specified, then following synthesis of random codons at the first position and mixing of the supports, the mixed supports are not divided into new reaction vessels but, instead, can be contained in a single reaction vessel to synthesize the  
35 specified codon. The specified codon is synthesized

sequentially from individual monomers as described above. Thus, the number of reaction vessels can be increased or decreased at each step to allow for the synthesis of a specified codon or a desired number of random codons.

- 5       Following codon synthesis, the mixed supports are divided into individual reaction vessels for synthesis of the next codon to be randomized (Figure 1, step 3) or can be used without separation for synthesis of a consecutive specified codon. The rounds of synthesis can be repeated  
10   for each codon to be added until the desired number of positions with predetermined or randomized codons are obtained.

- Synthesis of oligonucleotides with the first position codon being specified can also be synthesized using the  
15   above method. In this case, the first position codon is synthesized from the appropriate monomers. The supports are divided into the required number of reaction vessels needed for synthesis of random codons at the second position and the rounds of synthesis, mixing and dividing  
20   are performed as described above.

- The invention provides for a method of synthesizing oligonucleotides having tuplets which are diverse but biased toward a predetermined sequence. This method employs two reaction vessels, one vessel for the synthesis  
25   of a predetermined sequence and the second vessel for the synthesis of a random sequence. The method is advantageous to use when a significant number of codon positions, for example, are to be of a specified sequence since it alleviates the use of multiple reaction vessels. Instead,  
30   a mixture of four different monomers such as adenine, guanine, cytosine and thymine nucleotides are used for the first and second monomers in the codon position specifying the diverse sequence. The codon is completed by coupling a mixture of a pair of monomers of either guanine and

thymine or cytosine and adenine nucleotides at the third monomer position. In the second vessel, nucleotide monomers are coupled sequentially to yield the predetermined codon sequence. Mixing of the two supports yields a population of oligonucleotides containing both the predetermined codon and the random codons at the desired position. Synthesis can proceed by using this mixture of supports in a single reaction vessel, for example, for coupling additional predetermined codons or, further dividing the mixture into two reaction vessels for synthesis of additional random codons.

The two reaction vessel method can be used for codon synthesis within an oligonucleotide with a predetermined tuplet sequence by dividing the support mixture into two portions at the desired codon position to be randomized. Additionally, this method allows for the extent of randomization to be adjusted. For example, unequal mixing or dividing of the two supports will change the fraction of codons with predetermined sequences compared to those with random codons at the desired position. Unequal mixing and dividing of supports can be useful when there is a need to synthesize random codons at a significant number of positions within an oligonucleotide of a longer or shorter length.

The extent of randomization can also be adjusted by using unequal mixtures of monomers in the first, second and third monomer coupling steps of the random codon position. The unequal mixtures can be in any or all of the coupling steps to yield a population of codons enriched in sequences reflective of the monomer proportions.

The invention provides for oligonucleotides synthesized by the methods described herein. Synthesis of randomized oligonucleotides is performed using methods well known to one skilled in the art. Linear coupling of



15

monomers can, for example, be accomplished using phosphoramidite chemistry with a MilliGen/Biosearch Cyclone Plus automated synthesizer as described by the manufacturer (Millipore, Burlington, MA). Other chemistries and  
5 automated synthesizers can be employed as well and are known to one skilled in the art.

Synthesis of multiple codons can be performed without modification to the synthesizer by separately synthesizing the codons in individual sets of reactions. Alternatively,  
10 modification of an automated DNA synthesizer can be performed for the simultaneous synthesis of codons in multiple reaction vessels.

The following examples are intended to illustrate, but not limit the invention.

15

## EXAMPLE I

Synthesis of an Oligonucleotide with Random Codons  
Using Individual Monomers

This example demonstrates the synthesis of an antisense oligonucleotide of ten codons in length with  
20 twenty random codons at each position.

The reaction vessels were obtained from the manufacturer of the automated synthesizer (Millipore, Burlington, MA; supplier of MilliGen/Biosearch Cyclone Plus Synthesizer) and were obtained as packages consisting of  
25 empty reaction columns (1  $\mu$ mole), frits, crimps and plugs (MilliGen/Biosearch catalog # GEN 860458). Derivatized and underivatized control pc glass phosphoramidite nucleotides, and synthesis reagents were also obtained from MilliGen/Biosearch. Crimper and decrimper tools were  
30 obtained from Fisher Scientific Co., Pittsburgh, PA (Catalog numbers 06-406-20 and 06-406-25A, respectively).

## 16

Ten reaction columns are used for the synthesis of a ten codon random oligonucleotide. The oligonucleotide has 5 monomers at its 3' end of the sequence 5'GAGCT3' and 8 monomers at its 5' end of the sequence 5'AATTCAT3'. The synthesizer is fitted with a column derivatized with a thymine nucleotide (MilliGen/Biosearch # 0615.50) and is programmed to synthesize the sequences shown in Table I for each of ten columns in independent reaction sets. The sequence of the last three monomers (from right to left since synthesis proceeds 3' to 5') encode the indicated amino acids:

Table I

	<u>Column</u>	<u>Sequence</u>	<u>Amino Acids</u>
	column 1	AA(A/C)GAGCT	Phe and Val
15	column 2	AG(A/G)GAGCT	Ser and Pro
	column 3	AT(A/G)GAGCT	Tyr and His
	column 4	AC(A/G)GAGCT	Cys and Arg
	column 5	CA(G/T)GAGCT	Leu and Met
	column 6	CT(G/C)GAGCT	Gln and Glu
20	column 7	AG(T/C)GAGCT	Thr and Ala
	column 8	AT(T/C)GAGCT	Asn and Asp
	column 9	CC(A/C)GAGCT	Trp and Gly
	column 10	T(A/T)TGAGCT	Ile and Cys

where the two monomers in parentheses denote a single monomer position within the codon and indicate that an equal mixture of each monomer is added to the reaction for coupling. The monomer coupling reactions for each of the 10 columns are performed as recommended by the manufacturer (amidite version S1.06, # 8400-050990, scale 1  $\mu$ M). After the last coupling reaction, the columns are washed with acetonitrile and lyophilized to dryness.

Following synthesis, the plugs are removed from each column using a decrimper and the reaction products are

poured into a single weigh boat. Lost material is equalized with underivatized control pore glass and mixed thoroughly to obtain a random distribution of all twenty codon species. The reaction products are then aliquoted  
5 into 10 new reaction columns by removing 25 mg of material at a time and placing it into separate reaction columns. Alternatively, the reaction products can be aliquoted by suspending the beads in a liquid that is dense enough for the beads to remain dispersed, preferably a liquid that is  
10 equal in density to the beads, and then aliquoting equal volumes of the suspension into separate reaction columns. The lip on the inside of the columns where the frits rest are cleared of material using vacuum suction with a syringe and 25 G needle. New frits are placed onto the lips, the  
15 plugs are fitted into the columns and are crimped into place using a crimper.

Synthesis of the second codon position is achieved using the above 10 columns containing the random mixture of reaction products from the first codon synthesis. The  
20 monomer coupling reactions for the second codon position are shown in Table II. An A in the first position means that any monomer can be programmed into the synthesizer at that position since the first monomer position is not coupled by the synthesizer. An A also denotes that the  
25 columns from the previous codon synthesis should be placed on the synthesizer for use in the present synthesis round. Reactions are again sequentially repeated for each column as shown in Table II and described above, and the reaction products washed and dried.

Table II

	<u>Column</u>	<u>Sequence</u>	<u>Amino Acids</u>
	column 1	AA(A/C)A	Phe and Val
	column 2	AG(A/G)A	Ser and Pro
5	column 3	AT(A/G)A	Tyr and His
	column 4	AC(A/G)A	Cys and Arg
	column 5	CA(G/T)A	Leu and Met
	column 6	CT(G/C)A	Gln and Glu
	column 7	AG(T/C)A	Thr and Ala
10	column 8	AT(T/C)A	Asn and Asp
	column 9	CC(A/C)A	Trp and Gly
	column 10	T(A/T)TA	Ile and Cys

Randomization of the second codon position is achieved by removing the reaction products from each of the columns and thoroughly mixing the material. The material is again divided into new reaction columns and prepared for monomer coupling reactions as described above.

Random synthesis of the next seven codons (positions 3 through 9) proceeds identically to the cycle described above for the second codon position and again used the monomer sequences of Table II. Each of the newly repacked columns containing the random mixture of reaction products from synthesis of the previous codon position is used for the synthesis of the subsequent codon position. After synthesis of the codon at position nine and mixing of the reaction products, the material is divided and repacked into 40 different columns and the monomer sequences shown in Table III are coupled to each of the 40 columns in independent reactions. The oligonucleotides from each of the 40 columns are mixed once more and cleaved from the control pore glass as recommended by the manufacturer.

Table III

	<u>Column</u>	<u>Sequence</u>
	column 1	AATTCCATAAAA
5	column 2	AATTCCATAAAC
	column 3	AATTCCATAACA
	column 4	AATTCCATAACC
	column 5	AATTCCATAGAA
	column 6	AATTCCATAGAC
10	column 7	AATTCCATAGGA
	column 8	AATTCCATAGGC
	column 9	AATTCCATATAA
	column 10	AATTCCATATAC
	column 11	AATTCCATATGA
15	column 12	AATTCCATATGC
	column 13	AATTCCATACAA
	column 14	AATTCCATACAC
	column 15	AATTCCATACGA
	column 16	AATTCCATACGC
20	column 17	AATTCCATCAGA
	column 18	AATTCCATCAGC
	column 19	AATTCCATCATA
	column 20	AATTCCATCATC
	column 21	AATTCCATCTGA
25	column 22	AATTCCATCTGC
	column 23	AATTCCATCTCA
	column 24	AATTCCATCTCC
	column 25	AATTCCATAGTA
	column 26	AATTCCATAGTC
30	column 27	AATTCCATAGCA
	column 28	AATTCCATAGCC
	column 29	AATTCCATATTA
	column 30	AATTCCATATTC
	column 31	AATTCCATATCA
35	column 32	AATTCCATATCC
	column 33	AATTCCATCCAA
	column 34	AATTCCATCCAC

20

	column 35	AATTCCATCCCA
	column 36	AATTCCATCCCC
	column 37	AATTCCATTATA
	column 38	AATTCCATTATC
5	column 39	AATTCCATTTTA
	column 40	AATTCCATTTTC

## EXAMPLE II

Synthesis of a Randomized Oligonucleotides with  
Predetermined Positions Having Specified Codons

10        This example demonstrates the synthesis of a random oligonucleotide with the second position specifying the codon for methionine.

          Synthesis of a random oligonucleotide having a specified codon at the second position is accomplished  
15    identically to that described in Example I except that the monomer sequence synthesized at the second position is identical for all ten reaction columns. The reaction columns containing the random codons, after the first position synthesis, are placed on the synthesizer and all  
20    ten columns receive the identical sequence of monomer coupling reactions. For methionine being the specified codon at the second position, the sequence is ATG. After all the coupling reactions are performed, the resultant product is a dinucleotide with the first position being  
25    random and the second position having a methionine codon. The columns are then used for the ten coupling reactions, as described in Example I to synthesize random codons at the remaining positions.

## EXAMPLE III

Synthesis of Oligonucleotides Having Triplets which  
are Diverse but Biased Toward a Predetermined Sequence

This example demonstrates the use of the two column  
5 method for synthesis of a thirteen codon oligonucleotide in  
which five positions are diverse but biased toward a  
predetermined sequence.

Synthesis of the thirteen codon oligonucleotide was  
accomplished using the methods described in Example I. As  
10 an alternative, smaller beads having a capacity of 48 µg/g  
(Genta, San Diego, CA) can be used for the synthesis. Such  
beads are derivatized with a guanine nucleotide and do not  
have a controlled pore size. The first four codon  
positions as well as the last four positions of the  
15 oligonucleotide were synthesized to contain predetermined  
codon sequences. The middle five codon positions, however,  
were synthesized to contain a diverse sequence that was  
biased toward a predetermined sequence. The overall scheme  
can be depicted as the synthesis of the following two  
20 oligonucleotides where oligonucleotide (1) shows the  
sequence of the predetermined sequence and oligonucleotide  
(2) shows the positions of the five randomized codon  
positions:

25 (1) 5'- GTA CCA GTT CAT GAA ACT TAC  
ACT TCA GCT GGC CCT GCA - 3'

(2) 5'- GTA CCA GTT CAT C/ANN C/ANN  
C/ANN C/ANN C/ANN GCT GGC CCT GCA - 3'

The synthesis of the first four codon positions was  
accomplished by the sequential coupling of monomers in a  
30 single reaction column (5'- GCT GGC CCT GCA -3'). Since  
oligonucleotide synthesis proceeds in a 3'-to-5' direction,  
these first four synthesized positions correspond to the

last four codon positions of the desired oligonucleotide. After coupling of the last monomer, the column was unplugged and its contents divided into two equal portions as described previously. Each portion was then repacked  
 5 into two empty reaction columns. Reaction columns were plugged as described previously and the columns were placed on the synthesizer and programmed to synthesize the following sequences.

Table IV

10	<u>Column</u>	<u>Sequence</u>
	Column 1	TCAA
	Column 2	C/ANNA

Following synthesis the plugs were removed and the products were mixed, divided into two equal portions and  
 15 then repacked into new columns as described in Example I. Synthesis, mixing and dividing of the next four positions proceeded identical to that described above for the fifth synthesized position. The sequences coupled at each position for each of the two columns are shown below in  
 20 Table V.

Table V

	<u>Synthesized Position</u>	<u>Column</u>	<u>Sequence</u>
	6	Column 1	ACTA
		Column 2	C/ANNA
25	7	Column 1	TACA
		Column 2	C/ANNA
	8	Column 1	ACTA
		Column 2	C/ANNA
	9	Column 1	GAAA
30		Column 2	C/ANNA



Synthesized positions 10 through 13 were performed using a single reaction column that contained as the starting material the combined products of columns 1 and 2 after position 9 was synthesized. These last four  
5 positions were synthesized by the sequential coupling of individual monomers to yield a population of oligonucleotides in which the first four and the last four codon positions were of a predetermined sequence, and the middle five positions were diverse but biased toward a  
10 predetermined sequence.

The population of oligonucleotides synthesized above were cleaved and purified from the beads. Sequences of twenty-four randomly selected oligonucleotides were determined by DNA sequencing after their incorporation by  
15 mutagenesis into a M13-derived vector. Nine of these sequences contained the vector sequence and one contained a 1 bp deletion due to the synthesis or mutagenesis procedures. These ten oligonucleotide sequences were not incorporated into the analysis shown below. All of the  
20 remaining 14 oligonucleotide sequences had a codon different than that specified by the predetermined sequence incorporated at at least one position. Many of the oligonucleotide sequences had different codons at more than one position. (Two oligonucleotide sequences had only one  
25 position changed whereas four oligonucleotides had each of two, three or four different positions changed.) There were no oligonucleotide sequences found that contained different codons at all five positions. However, in subsequent analysis of further selected clones,  
30 oligonucleotide sequences were found that contained different codons at all five positions. The frequency of different codons obtained at randomized positions 5 through 9 of the thirteen codon oligonucleotides is shown below in Table VI.

Table VI

		<u>NUMBER OBTAINED</u>	
		<u>Predetermined</u>	<u>Random</u>
5	<u>Codon Position</u>	<u>Codon Sequences</u>	<u>Codon Sequences</u>
	5	9	5
	6	5	9
	7	5	9
	8	9	5
10	9	4	10

These results demonstrate that oligonucleotides can be synthesized using the two-column method described herein to obtain a population of oligonucleotides biased toward a predetermined sequence but having diverse codon sequences at one or more positions.

**EXAMPLE IV**

The Use of Liquid Suspensions for Mixing and  
Dividing Reaction Products

This example shows the use of liquid suspensions for the aliquoting of equal volumes of reaction products at each mixing and dividing step.

The mixing and dividing steps described in Example I for generating random distributions of reaction products have been performed by the alternative method of dispensing equal volumes of bead suspensions. The liquid chosen that is dense enough for the beads to remain dispersed was 100% acetonitrile.

Briefly, each column was prepared for the first coupling reaction by suspending 22 mg (1 $\mu$ mole) of 48  $\mu$ g/g capacity beads (Genta, San Diego, CA) in 0.5 mls of 100% acetonitrile and transferring this suspension to an empty

reaction column. The beads were kept relatively dispersed by gently pipetting the suspension during transfer. Columns were plugged and monomer coupling reactions were performed for each desired codon. After coupling of the  
5 last monomer for each desired codon, the columns were unplugged as described previously and their contents were poured into a 50 ml conical centrifuge tube. The columns were rinsed with 100% acetonitrile to recover any remaining beads. The volume used for rinsing was determined so that  
10 the final volume of total bead suspension was about 0.5 mls for each new reaction column that the beads would be aliquoted into. The mixture was vortexed gently to produce a uniformly dispersed suspension and then divided, with constant pipetting of the mixture, into equal volumes.  
15 Each mixture of beads was then transferred to an empty reaction column. The empty tubes were washed with a small volume of 100% acetonitrile and also transferred to their respective columns.

Although the invention has been described with  
20 reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.

I claim:

1. A method of synthesizing oligonucleotides having random tuplets using individual monomers comprising the steps of:

- 5 (1) sequentially coupling monomers on separate supports to form at least two different tuplets, said coupling being performed in separate reaction vessels;
- (2) mixing the supports from the separate reaction vessels;
- 10 (3) dividing the mixed supports into two or more separate reaction vessels; and
- (4) repeating steps (1) through (3) one or more times in the reaction vessels of step (3), wherein the last step ends at  
15 step (2).

2. The method of claim 1 further comprising step (5) cleaving said oligonucleotides with random tuplets from said support.

3. The method of claim 1, wherein the tuplet is a triplet.

4. The method of claim 1, wherein the number of tuplets to be randomized is between two and twenty.

5. The method of claim 1, wherein the number of reaction vessels is equal to the number of tuplets to be randomized.

6. The method of claim 5, wherein each tuplet to be randomized is coupled in a separate reaction vessel.

7. The method of claim 1, wherein the number of reaction vessels is less than the number of tuplets to be randomized.

8. The method of claim 7, wherein two tuplets to be randomized are coupled to a support in a reaction vessel.

9. The method of claim 7, wherein the first, second and third monomers of the tuple are selected from the group comprising (T/G)TT, (T/C)CT, (T/C)AT, (T/C)GT, (C/A)TG, (C/G)AG, (A/G)CT, (A/G)AT, (T/G)GG and A(T/A)A.

10. A method of synthesizing oligonucleotides using individual monomers having at least one specified tuple at a predetermined position and the remaining positions having random tuples comprising the method of  
5 claim 1, wherein said specified tuple position is synthesized on the mixed supports prior to dividing into separate reaction vessels.

11. The method of claim 10, wherein the first position is predetermined and the specified tuple is synthesized prior to step (1).

12. A method of synthesizing oligonucleotides having tuplets which are diverse but biased toward a predetermined sequence comprising the steps of:

- 5                   (1) sequentially coupling monomers on a support to form a tuplet with a predetermined sequence, said coupling being performed in a first reaction vessel;
- 10                  (2) sequentially coupling monomers on a support to form a random tuplet, said coupling being performed in a second reaction vessel;
- (3) mixing the supports from said first and second reaction vessels; and
- 15                  (4) dividing the mixed supports from step (3) and using the supports in step (1) and step (2), wherein steps (1) through (3) are repeated at least once.

13. The method of claim 12 further comprising step (4) cleaving said oligonucleotide from said support.

14. The method of claim 12, wherein said tuplet is a triplet and step (2) further comprises:

- 5 (2a) coupling a mixture of four different monomers for the first monomer of the random triplet;
- (2b) coupling a mixture of four different monomers for the second monomer of the random triplet; and
- 10 (2c) coupling a pair of monomers selected from the group consisting of guanine and thymine or cytosine and adenine monomers for the third monomer of the random triplet to form a random triplet.

15. The method of claim 14, wherein the four different monomers are adenine, guanine, cytosine and thymine.

16. The method of claim 14, wherein four different monomers in step (2a) or (2b) are present in equal proportions.

17. The method of claim 14, wherein the four different monomers in steps (2a) and (2b) are present in equal proportions.

18. The method of claim 14, wherein the four different monomers in steps (2a) or (2b) are present in unequal proportions.

19. The method of claim 14, wherein the four different monomers in steps (2a) and (2b) are present in unequal proportions.

20. The method of claim 14, wherein the guanine and thymine monomers of step (2c) are present in equal proportions.

21. The method of claim 14, wherein the guanine and thymine monomers of step (2c) are present in unequal proportions.

22. The method of claim 12, wherein the mixed supports from said first and second reaction vessels are divided into equal proportions.


23. The method of claim 12, wherein the mixed supports from said first and second reaction vessels are divided into unequal proportions.

24. Oligonucleotides synthesized by the method of claim 1.

25. Oligonucleotides synthesized by the method of claim 12.




FIG. 1



2 / 2

FIG. 2



SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/05939

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C07H 17/00 U.S.C1: 536/27, 28, 29																	
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; text-align: left; border-bottom: 1px solid black;">Classification System</th> <th style="text-align: left; border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">U.S. C1:</td> <td style="padding: 5px;">536/27, 28, 29</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup></div> <div style="padding: 5px; text-align: center;">CAS, APS</div>			Classification System	Classification Symbols	U.S. C1:	536/27, 28, 29											
Classification System	Classification Symbols																
U.S. C1:	536/27, 28, 29																
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; text-align: center; padding: 5px;">Category <sup>10</sup></th> <th style="text-align: left; padding: 5px;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 15%; text-align: center; padding: 5px;">Relevant to Claim No. <sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">US, A, 4,458,066 (Caruthers et al) 03 July 1984, see col. 2-col. 3.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-25</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">EP, A, 0,383,620 (Cook) 22 August 1990, see page 8.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-25</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">R. Adams et al., "The Biochemistry of Nucleic Acids" published 1986 by Chapman and Hall (London/New York) see pages 11-13.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">24-25</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">Federation Proceedings, volume 42, No. 7, issued 01 May 1983, Blake et al. 'Triplet Analysis of DNA sequences' page 2264, see abstract 2958.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-25</td> </tr> </tbody> </table>			Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	Y	US, A, 4,458,066 (Caruthers et al) 03 July 1984, see col. 2-col. 3.	1-25	Y	EP, A, 0,383,620 (Cook) 22 August 1990, see page 8.	1-25	Y	R. Adams et al., "The Biochemistry of Nucleic Acids" published 1986 by Chapman and Hall (London/New York) see pages 11-13.	24-25	A	Federation Proceedings, volume 42, No. 7, issued 01 May 1983, Blake et al. 'Triplet Analysis of DNA sequences' page 2264, see abstract 2958.	1-25
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>															
Y	US, A, 4,458,066 (Caruthers et al) 03 July 1984, see col. 2-col. 3.	1-25															
Y	EP, A, 0,383,620 (Cook) 22 August 1990, see page 8.	1-25															
Y	R. Adams et al., "The Biochemistry of Nucleic Acids" published 1986 by Chapman and Hall (London/New York) see pages 11-13.	24-25															
A	Federation Proceedings, volume 42, No. 7, issued 01 May 1983, Blake et al. 'Triplet Analysis of DNA sequences' page 2264, see abstract 2958.	1-25															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents: <sup>14</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>																	
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;">           Date of the Actual Completion of the International Search  <b>04 October 1991</b> </td> <td style="width: 50%; vertical-align: top; padding: 5px;">           Date of Mailing of this International Search Report  <b>14 NOV 1991</b> </td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">           International Searching Authority  <b>ISA/US</b> </td> <td style="vertical-align: top; padding: 5px;">           Signature of Authorized Officer    <b>A. Varma</b> </td> </tr> </table>			Date of the Actual Completion of the International Search <b>04 October 1991</b>	Date of Mailing of this International Search Report <b>14 NOV 1991</b>	International Searching Authority <b>ISA/US</b>	Signature of Authorized Officer  <b>A. Varma</b>											
Date of the Actual Completion of the International Search <b>04 October 1991</b>	Date of Mailing of this International Search Report <b>14 NOV 1991</b>																
International Searching Authority <b>ISA/US</b>	Signature of Authorized Officer  <b>A. Varma</b>																



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> <b>C07K 7/06, A61K 31/195,</b> <b>A61K 38/08, A61K 38/10,</b> <b>A61K 47/48, C07K 7/08,</b> <b>G01N 33/566, G01N 33/68</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/46284</b> <b>(43) International Publication Date:</b> 16 September 1999 (16.09.1999)
<b>(21) International Application Number:</b> PCT/US99/05284 <b>(22) International Filing Date:</b> 10 March 1999 (10.03.1999) <b>(30) Priority Data:</b> 09/042,107      13 March 1998 (13.03.1998) US 09/258,754      26 February 1999 (26.02.1999) US <b>(60) Parent Application or Grant</b> THE BURNHAM INSTITUTE [/]; O. RAJOTTE, Daniel [/]; O. PASQUALINI, Renata [/]; O. RUOSLAHTI, Erkki, I. [/]; O. GASHLER, Andrea, L.; O.		<b>Published</b>
<b>(54) Title: MOLECULES THAT HOME TO VARIOUS SELECTED ORGANS OR TISSUES</b> <b>(54) Titre: MOLECULES SE LOGEANT DANS DIVERS ORGANES OU TISSUS/ISSUES</b>		
<b>(57) Abstract</b> <p>The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a moiety can be, for example, a therapeutic agent or a detectable agent. The invention also provides a method of identifying a membrane dipeptidase (MDP)-binding homing molecule that selectively homes to lung endothelium. The method includes the steps of contacting MDP with one or more molecules; and determining specific binding of a molecule to the MDP, where the presence of specific binding identifies the molecule as a MDP-binding homing molecule that selectively homes to lung endothelium. Such MDP-binding homing molecules can be linked to a moiety and, when administered to a subject as a conjugate, can selectively direct the moiety to lung endothelium in the subject.</p> <b>(57) Abrégé</b> <p>La présente invention concerne des molécules qui se logent sélectivement dans des organes ou dans des tissus normaux, notamment les poumons, le pancréas, la peau, la rétine, la prostate, les ovaires, les ganglions lymphatiques, la glande surrénale, le foie, ou l'intestin. La présente invention concerne également des molécules qui se logent sélectivement dans des organes ou dans des tissus tumoraux, notamment le pancréas porteur d'une tumeur du pancréas, ou les poumons porteurs d'une tumeur des poumons. Cette invention concerne en outre des conjugués renfermant une molécule qui se loge dans un organe ou dans un tissu, cette molécule étant liée à un fragment, qui peut par exemple être un agent thérapeutique ou un agent détectable. Cette invention concerne par ailleurs une méthode d'identification d'une molécule fixée à l'enzyme MDP, cette molécule se logeant sélectivement dans l'endothélium des poumons. Cette méthode consiste tout d'abord à mettre la MDP en présence d'une ou plusieurs molécules, puis à déterminer la fixation spécifique d'une molécule à cette MDP, la présence d'une fixation spécifique permettant d'identifier cette molécule comme une molécule fixée à la MDP et se logeant sélectivement dans l'endothélium des poumons. Ces molécules fixées à la MDP et se logeant dans un organe ou dans un tissu peuvent être liées à un fragment, et une fois administrées à un sujet sous la forme d'un conjugué, peuvent diriger sélectivement ce fragment sur l'endothélium des poumons du sujet.</p>		

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**